Hemispherx Biopharma (HEB) Cash Flow Statement

Click line-items for a historical chart and %

Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	576K
Amortization of patent and trademark rights, and royalty interest
Redeemable warrants valuation adjustment
Equity based compensation
Gain on disposal of equipment
Change in assets and liabilities:
Inventories	0
Prepaid expenses and other current assets
Accounts payable	178K
Accrued expenses	1.82M
Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment	-160K
Additions to patent and trademark rights	-207K
Deposits on capital leases
Maturities of short-term and long-term investments	1.92M
Purchase of short-term and long-term investments
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Payments on capital lease
Proceeds from sale of stock, net of issuance costs	163K
Net cash provided by (used in) financing activities
Net decrease in cash and cash equivalents	-577K
Cash and cash equivalents at beginning of period	2.12M
Cash and cash equivalents at end of period	1.54M
Supplemental disclosures of non-cash investing and financing cash flow information:
Issuance of common stock for accounts payable and accrued expenses
Equipment acquired by capital lease
Unrealized gain (loss) on investments
Redeemable warrants valuation adjustment
Supplemental disclosure of cash flow information:
Cash paid for interest expense

Entities mentioned with HEB